Hu ZI, Bendell JC, Bullock A, et al. - In patients with metastatic pancreatic adenocarcinoma (PDAC), researchers assessed the activity of tarextumab (a fully human IgG2 antibody that inhibits Notch2/3 receptors) in combination with nab-paclitaxel and gemcitabine in a phase 2, randomized, placebo-controlled, multicenter trial. On the basis of the Eastern Cooperative Oncology Group performance score and Ca 19-9 level, the stratification of patients was done. Using 1:1 randomization, patients were allocated to nab-paclitaxel, gemcitabine with either tarextumab or placebo. In first-line metastatic PDAC, no improvement was evident in overall survival, progression-free survival (PFS), or overall response rate when tarextumab was added to nab-paclitaxel and gemcitabine. The tarextumab-treated patients specifically showed a statistical worsening of PFS.